THE DAY, IN CONTEXTPolaris InsightsAn AI-powered comprehensive news portal

POLARIS INSIGHTS

Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying

As part of the agreement, Hims said it won’t compound GLP-1 medications like Zepbound in the future.

Read the full account of the story

More from the Markets desk

More from Markets · Back to Polaris Insights